These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19182367)

  • 1. [To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
    Maruyama T; Kadowaki D
    Clin Calcium; 2009 Feb; 19(2):248-52. PubMed ID: 19182367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
    Wilson RJ; Keith MS; Preston P; Copley JB
    Adv Ther; 2013 Dec; 30(12):1100-10. PubMed ID: 24307220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
    Negi S; Shigematsu T
    Clin Calcium; 2010 Jul; 20(7):1096-102. PubMed ID: 20585189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of phosphate binder in predialysis patients].
    Taniguchi M
    Clin Calcium; 2009 Feb; 19(2):229-35. PubMed ID: 19182364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
    Hanba Y; Masumoto A; Moribata M; Shigemathu T
    Clin Calcium; 2012 Jul; 22(7):1059-71. PubMed ID: 22750939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
    Tatsuta K; Shigematsu T
    Clin Calcium; 2009 Feb; 19(2):219-23. PubMed ID: 19182362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is lanthanum carbonate a safe drug?].
    Kazama JJ
    Clin Calcium; 2009 Feb; 19(2):224-8. PubMed ID: 19182363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
    Mehrotra R; Martin KJ; Fishbane S; Sprague SM; Zeig S; Anger M;
    Clin J Am Soc Nephrol; 2008 Sep; 3(5):1437-45. PubMed ID: 18579668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
    Koiwa F; Sato Y
    Clin Calcium; 2009 Feb; 19(2):198-204. PubMed ID: 19182359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reasons for phosphate binder discontinuation vary by binder type.
    Wang S; Anum EA; Ramakrishnan K; Alfieri T; Braunhofer P; Newsome B
    J Ren Nutr; 2014 Mar; 24(2):105-9. PubMed ID: 24462496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral phosphate binders in patients with kidney failure.
    Tonelli M; Pannu N; Manns B
    N Engl J Med; 2010 Apr; 362(14):1312-24. PubMed ID: 20375408
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
    Koizumi M; Fukagawa M
    Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
    Ketteler M
    Int J Artif Organs; 2009 Feb; 32(2):95-100. PubMed ID: 19363781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of hyperphosphatemia ; phosphate-binder].
    Yokoyama K
    Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
    Arenas MD; Rebollo P; Malek T; Moledous A; Gil MT; Alvarez-Ude F; Morales A; Cotilla E
    J Nephrol; 2010; 23(6):683-92. PubMed ID: 20540040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel phosphate binders under development].
    Mizobuchi M; Sanada D; Akizawa T
    Clin Calcium; 2009 Feb; 19(2):237-41. PubMed ID: 19182365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
    Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
    Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.